NPY2R

NPY2R is a Gi-coupled neuropeptide Y receptor that functions as a key integrator of peptidergic signaling across neural, renal, cartilaginous, and glandular tissues, primarily transducing NPY and PYY signals into inhibition of cAMP and activation of PI3K, MAPK, NFAT, and mTORC1 cascades. Encoded by a two-exon gene on chromosome 4q31 with an intronless coding region, NPY2R inhibits cAMP production upon ligand binding and, in a tissue-dependent manner, engages mTORC1–S6K1–SMAD–Runx2 signaling to drive chondrocyte hypertrophy in articular cartilage (PMID:32101625) or PI3K/MAPK/NFAT signaling in podocytes to regulate cell migration and albuminuria (PMID:32561647). In the nervous system, NPY2R activation reduces food intake and gastric emptying (PMID:40619099), mediates late-phase fear memory extinction in hippocampal sub-ensembles, and defines a population of pulmonary vagal sensory neurons that project to brainstem and periaqueductal gray to produce analgesia (PMID:40874463). NPY2R also forms a complex with NPY5R and NFATc1 in sebaceous glands, positioning it upstream of the DYRK1A/NFATc1 transcriptional axis that controls sebum gene expression (PMID:37501148).

1. 1996 High

   Cloning of the human NPY2R gene established it as a GPCR encoded by two exons on chromosome 4q31, resolving its genomic organization and evolutionary relationship to NPY1R via likely gene duplication.

   Evidence Gene cloning, Northern analysis, and chromosomal mapping of the human NPY2R locus

   PMID:8975716

   Open questions at the time

   • No signal transduction pathway defined at this stage
   • Tissue-specific expression patterns only partially characterized by Northern blot
   • Ligand selectivity profile not fully delineated
2. 2014 Medium

   A functional NPY2R promoter variant was linked to Huntington disease age of onset, and NPY2R agonism was shown to protect against mutant huntingtin-induced cell death, establishing a neuroprotective role for NPY2R signaling.

   Evidence Luciferase promoter reporter assays and cell death assays in PC12 cells expressing mutant huntingtin treated with NPY2R agonist NPY(3-36)

   PMID:24121255

   Open questions at the time

   • Neuroprotective downstream mechanism not identified
   • In vivo validation in Huntington disease models lacking
   • Whether the promoter SNP effect is cell-type specific is unknown
3. 2018 Medium

   Direct demonstration that NPY2R activation by PYY(3-36) inhibits cAMP production and can suppress adenosine-stimulated cAMP, defining the canonical Gi-coupled signaling output of the receptor.

   Evidence FRET-based real-time cAMP assay in living cells co-expressing NPY2R and adenosine A2B receptor

   PMID:29491394

   Open questions at the time

   • G-protein coupling specificity (Gi subtypes) not resolved
   • Downstream effectors beyond cAMP inhibition not addressed
   • Endogenous tissue context not tested
4. 2019 Medium

   Pharmacological studies in Xenopus tectum showed that NPY2R mediates suppression of prey-capture and food intake, establishing an evolutionarily conserved role for NPY2R in feeding and predator-avoidance behavior.

   Evidence Bilateral tectal microinjection of NPY and NPY2R-specific antagonist BIIE0246 with behavioral assays in Xenopus laevis

   PMID:31271760

   Open questions at the time

   • Non-mammalian system; direct applicability to mammalian hypothalamic circuits uncertain
   • Downstream intracellular signaling in tectal neurons not characterized
   • Cell-type identity of NPY2R-expressing tectal neurons unknown
5. 2020 High

   Two studies concurrently revealed tissue-specific NPY2R downstream signaling: in chondrocytes, NPY2R activates mTORC1–S6K1 which phosphorylates SMAD1/5/8 and promotes Runx2-driven hypertrophy; in podocytes, NPY2R engages PI3K, MAPK, and NFAT to modulate migration and albuminuria, demonstrating that NPY2R couples to distinct effector pathways depending on cell type.

   Evidence NPY2R antagonist and rapamycin in chondrocytes with kinase-substrate interaction assays in vitro and intra-articular NPY in vivo [PMID:32101625]; PI3K/MAPK/NFAT signaling assays in podocytes, proteomics, NPY-KO mice, and NPY2R pharmacological inhibition in adriamycin nephropathy model [PMID:32561647]

   PMID:32101625 PMID:32561647

   Open questions at the time

   • How NPY2R selectively engages mTORC1 versus PI3K/MAPK/NFAT in different cell types is unknown
   • Identity of the G-protein or adaptor mediating pathway divergence not defined
   • Whether NPY2R signals through beta-arrestin in these contexts is untested
6. 2023 Medium

   Discovery that NPY2R forms a physical complex with NPY5R and NFATc1 in sebaceous glands placed NPY2R upstream of DYRK1A-regulated NFATc1 nuclear translocation and sebum gene transcription, revealing a non-canonical signaling mode involving receptor hetero-complexation.

   Evidence Co-immunoprecipitation, mass spectrometry, gel filtration for complex identification; ChIP-seq for NFATc1 genomic occupancy in sebocytes

   PMID:37501148

   Open questions at the time

   • Stoichiometry and direct versus indirect interaction between NPY2R and NPY5R not resolved
   • Whether NPY2R–NPY5R complex signals differently from NPY2R alone is untested
   • Functional consequence of disrupting the complex on sebaceous differentiation in vivo not shown
7. 2024 Medium

   Single-cell transcriptomics and CRISPR knockout in ventral hippocampal CA1 demonstrated that NPY2R-expressing neuronal sub-ensembles are functionally distinct from NPY1R ensembles and specifically govern late-phase fear memory extinction, establishing a circuit-level role for NPY2R in memory stability.

   Evidence Activity-dependent scRNA-seq, genetically encoded NPY sensors, CRISPR/Cas9 NPY2R knockout, chemogenetic/optogenetic manipulation, and calcium imaging during fear conditioning in mice (preprint)

   PMID:bio_10.1101_2024.05.09.593455

   Open questions at the time

   • Preprint; not yet peer-reviewed
   • Intracellular signaling cascade downstream of NPY2R in hippocampal extinction neurons not characterized
   • Whether NPY2R modulates other forms of learning or only fear extinction is unknown
8. 2025 Medium

   Two 2025 studies expanded NPY2R's physiological roles: a long-acting NPY2R agonist demonstrated dose-dependent anorexigenic and gastric emptying effects synergistic with GLP-1R/GCGR agonism in obesity, while a separate study identified Npy2r-expressing pulmonary vagal neurons as mediators of MSC-derived analgesic signaling via a lung-to-brain circuit through NTS and vlPAG.

   Evidence In vivo pharmacology with BI 1820237 in lean and diet-induced obese mice [PMID:40619099]; chemogenetic DREADD activation of Npy2r vagal neurons, circuit tracing, and pain behavior assays in murine models [PMID:40874463]

   PMID:40619099 PMID:40874463

   Open questions at the time

   • Whether NPY2R agonism has direct central versus peripheral anorexigenic effects is unresolved
   • The ligand activating NPY2R on pulmonary vagal neurons (NPY versus PYY versus other) is not identified
   • Human translational data for both anti-obesity and analgesic applications absent

• The mechanism by which NPY2R engages distinct downstream cascades (cAMP inhibition, mTORC1, PI3K/MAPK, NFAT) in a cell-type-specific manner — and whether this involves differential G-protein coupling, beta-arrestin recruitment, or receptor heteromerization — remains unresolved.
• No structural model of NPY2R in complex with G-proteins or beta-arrestin
• Cell-type-specific signaling bias not mechanistically explained
• Role of NPY2R internalization and trafficking in signal diversification untested